Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Letter to the Editor

SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia

Authors: Francesco Albano, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Paola Casieri, Angela Minervini, Giorgina Specchia

Published in: Journal of Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

The molecular pathogenesis underlying the primary myelofibrosis (PMF) progression to acute myeloid leukemia (AML) is still not well defined. The involvement of microRNA (miRNA) is actually helping to shed light on an important issue in the occurrence of myeloproliferative neoplasms (MPNs). However, the role of intronic miRNA, derived from the intron regions of gene transcripts, has never been reported in MPNs. In this study, we describe a PMF case evolved to AML with a t(12;18)(p13;q12) rearrangement showing the downregulation of the intronic miR_4319 and the overexpression of its host gene, SET binding protein (SETBP1). A possible molecular mechanism regulating the PMF progression to AML is discussed.
Appendix
Available only for authorised users
Literature
1.
Vardiman JW, Brunning RD, Arber DA, Le Beau MM, Porwit A, Tefferi A: Introduction and overview of the classification of the myeloid neoplasms. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Edited by: Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008, Lyon: International Agency for Research on Cancer, 18-30. 4
2.
Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, Ponziani V, Poli G, Zini R, Ferrari S, Manfredini R, Bosi A, Vannucchi AM: MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol. 2007, 35: 1708-1718.CrossRefPubMed
3.
Hussein K, Theophile K, Dralle W, Wiese B, Kreipe H, Bock O: MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia. Platelets. 2009, 20: 391-400. 10.1080/09537100903114537.CrossRefPubMed
4.
Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A, Vainchenker W, Giraudier S, Constantinescu SN: miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood. 2010, 116: 437-445. 10.1182/blood-2008-06-165985.CrossRefPubMed
5.
Lutter D, Marr C, Krumsiek J, Lang EW, Theis FJ: Intronic microRNAs support their host genes by mediating synergistic and antagonistic regulatory effects. BMC Genomics. 2010, 11: 224-10.1186/1471-2164-11-224.PubMedCentralCrossRefPubMed
6.
Cristóbal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, Novo FJ, Bandres E, Calasanz MJ, Bernabeu C, Odero MD: SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood. 2010, 115: 615-625. 10.1182/blood-2009-06-227363.CrossRefPubMed
7.
Cristóbal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD: PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia. 2011, 25: 606-614. 10.1038/leu.2010.294.CrossRefPubMed
8.
Monteys AM, Spengler RM, Wan J, Tecedor L, Lennox KA, Xing Y, Davidson BL: Structure and activity of putative intronic miRNA promoters. RNA. 2010, 16: 495-505. 10.1261/rna.1731910.PubMedCentralCrossRefPubMed
Metadata
Title
SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia
Authors
Francesco Albano
Luisa Anelli
Antonella Zagaria
Nicoletta Coccaro
Paola Casieri
Angela Minervini
Giorgina Specchia
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-48

Other articles of this Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue

Rapid communication

Novel human polyomaviruses, Merkel cell polyomavirus and human polyomavirus 9, in Japanese chronic lymphocytic leukemia cases

Letter to the Editor

A novel monoclonal antibody of human stem cell factor inhibits umbilical cord blood stem cell ex vivo expansion

Rapid communication

Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols

Rapid communication

The significance of low PU.1 expression in patients with acute promyelocytic leukemia

Letter to the Editor

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw

Review

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits